Abstract
The aim of this study was to evaluate the screening and diagnostic validity of the initial serum S100 levels by Elecsys S100 immunoassay in an emergency department. We measured serum S100 in 101 acute brain injury (ABI) patients, in 40 healthy subjects, and in 41 chronic brain injury (CBI) patients (the control group). The ABI patients were divided in several groups according to the Glasgow Coma Scale (GCS), injury type and findings of brain imaging. Of the 101 patients, the 66 cranial computed tomography (CCT) or brain magnetic resonance imaging (MRI)-positive patients showed higher S100 levels than did the 35 CCT/MRI-negative patients (P=0.028). At a cutoff of 0.105 microg/L, the sensitivity was 84.8% and the specificity 74.3% for all of the ABI patients, and the sensitivity was increased to 96.9% for the traumatic ABI patients for detecting image-positive ABI. There was no significant difference of S100 levels among the groups on the CCT or MRI pathological findings (P=0.478). In conclusion, serum S100 levels can be used in the emergency department as an additional screening tool to identify CCT- or MRI-positive ABI.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
